Policy Correspondence | CSRO - Coalition of State Rheumatology Organizations

Donate
Contact
×

Search CSRO

Policy Correspondence

CSRO has templates available for rheumatology practices to contact insurers and other payers here.

2023

CSRO Correspondence

CSRO Letter RE: Health Care Workforce Shortages RFI
March 20, 2023
CSRO Letter RE: Feedback on Field Testing of the Rheumatoid Arthritis Episode Based Cost Measure
February 14, 2023
CSRO Letter RE: Medicare Program; Contract Year 2024 Policy and Technical Changes to the Medicare Advantage Program
February 13, 2023
CSRO Letter to Blue Cross Blue Shield of North Carolina
January 3, 2023

From our Partners

ASM Letter RE: Health Care Workforce Shortages RFI
March 20, 2023
ASM Letter RE: Advancing Interoperability and Improving Prior Authorization Processes
March 13, 2023
ASM Letter RE: Medicare Program; Contract Year 2024 Policy and Technical Changes
February 13, 2023
Letter RE: Step Therapy for Part B Drugs in Medicare Advantage
February 13, 2023
ASM Letter RE: Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2024
January 30, 2023
ACCC Letter RE: HHS Notice of Benefit and Payment Parameters for 2024 Proposed Rule, CMS-9899-P RIN 0938- AU97
January 30, 2023

2022

CSRO Correspondence

CSRO Letter RE: Precision Medicine Applications in Autoimmune Conditions
December 5, 2022
CSRO Letter RE: Nondiscrimination in Health Programs and Activities (1557 NPRM (RIN 0945-AA17))
September 21, 2022
CSRO Letter RE: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy in Rheumatoid Arthritis (DL39424)
September 17, 2022
CSRO Letter RE: Requests for Information (RFI) on the Medicare Advantage Program
August 30, 2022
CSRO Letter RE: Medicare and Medicaid Programs; CY 2023 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment Policies
August 25, 2022
CSRO Letter RE: FTC-2022-0015-0001
May 12, 2022
CSRO Letter RE: Proposed Rules for 28 TAC §19.1730 - 19.1733 & 28 TAC §12.601 relating to the Prior Authorization Exemptions
May 9, 2022
CSRO Letter RE: Call for Public Comment on Wave 5 Measure Development – Rheumatoid Arthritis
March 25, 2022
CSRO Letter RE: Predictive Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis Contractor Advisory Committee (CAC)
January 31, 2022
Correspondence between CSRO and Blue Cross Blue Shield of South Carolina Re: Non-Medical Switching Policy Update Concerns
- Initial Letter from CSRO to Blue Cross Blue Shield (December 13, 2021)
- Response from Blue Cross Blue Shield (December 17, 2021)
- Follow-up Letter from CSRO to Blue Cross Blue Shield (January 18, 2022)

From our Partners

ASM Letter RE: Options for Increasing Medicare Payment for Primary Care
December 6, 2022
ASM Letter RE: FTC-2022-0015-0001
May 17, 2022
ATAP Letter RE: FTC-2022-0015-0001
May 11, 2022
ASM Letter RE: Recommendations to Improve Utilization Management and Advance Specialty-Focused Alternative Payment Models
April 25, 2022
Letter RE: Oregon Waiver Renewal Application
April 11, 2022
ASM Letter RE: Request for Information: Electronic Prior Authorization Standards, Implementation Specifications, and Certification Criteria
March 18, 2022
ASM Letter RE: Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies (CMS-2022-0021)
March 4, 2022
ASM Letter RE: Request for Congressional Hearings on MACRA
February 18, 2022
ACCC Letter RE: Comments on HHS Notice of Benefit and Payment Parameters for 2023 Proposed Rule, CMS-9911-P RIN 0938-AU65
January 27, 2022
ASM Letter RE: Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2023
January 27, 2022
Letter RE: Support for S.644 and H.1053
January 27, 2022
Letter RE: Support for LD 1783
January 25, 2022

2021

CSRO Correspondence

From our Partners

2020-2017 Correspondence

CSRO Memo re Recent Complaints about Vivio Practices
February 26, 2020
CSRO Comments RE: UHC December Bulletin announcement to change the medical benefits for commercial and community plan patients who are currently stable on REMICADE® (infliximab)
December 22, 2020
CSRO Comments RE: CMS-5528-IFC, “Most Favored Nation Model” interim final rule with comment period
December 14, 2020
CRA Letter to Anthem Re Whitebagging SPP Mandate
October 26, 2020
CSRO Comments RE: CMS-2842-P (Medicaid AMP Calculation)
July 15, 2020
CSRO Press Release Re: Implementation of BCBST White-bagging Policy
July 1, 2020
CSRO Press Release Re: Patient Impact of BCBST White-bagging Policy
June 23, 2020
CSRO Press Release Re: Tennessee Employers Adopting BCBST White-bagging Policy
June 18, 2020
CSRO Letter to TN Chamber of Commerce re: BCBST White-bagging Policy
June 11, 2020
CSRO Letter to BCBST re: Mandatory White-bagging
June 5, 2020
CSRO Comments to CMS re: COVID-19 Telehealth and Home Administration Services
April 27, 2020
CSRO Memo to MACs Re: Addition of Stelara to SAD List
April 22, 2020
CSRO’s Compounding HCQ Letter to HHS
April 14, 2020
CSRO Joint Letter to CMS Re: Addition of Stelara to SAD List
April 8, 2020
CSRO Submits HR 3 Comments
November 26, 2019
CSRO Submits IPI Comments
December 31, 2018
CSRO Memo to UHG RE: Downcoding for Infusion Administration Services
October 22, 2018
CSRO Comments on CAP RFI OPPS
September 25, 2018
CSRO Comments to CMS on 2019 MPFS QPP NPRM
September 10, 2018
CSRO Biosimilar Pass-Through Support - Memo to Congress
March 15, 2018
Comments by CSRO and Cosignatories to Anthem on HA Injections
September 26, 2017
Comments by the CSRO on the Medicare Physician Fee Schedule (CMS-1676-P) Proposed Revisions
September 11, 2017
H.B. 260 – Relating to the regulation of biosimilar medications
February 6, 2017

We use cookies so that we can remember you and understand how you use our site. If you do not agree with our use of cookies, please change the current settings found in our Cookie Policy. Otherwise, you agree to the use of the cookies as they are currently set. To learn more, please visit our Privacy Policy.